Kyongbo Pharmaceutical Co Ltd (214390) — Cash Flow Reinvestment Rate
Kyongbo Pharmaceutical Co Ltd (214390) has a Cash Flow Reinvestment Rate of 3.78x as of September 2025, reinvesting ₩17.04 Billion (capex ₩17.04 Billion ) from operating cash flow of ₩4.51 Billion. Explore Kyongbo Pharmaceutical Co Ltd capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Kyongbo Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Kyongbo Pharmaceutical Co Ltd across 10 annual periods. Also explore Kyongbo Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Kyongbo Pharmaceutical Co Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Kyongbo Pharmaceutical Co Ltd. For live market cap and broader valuation context, see market value of Kyongbo Pharmaceutical Co Ltd.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 95.93x | ₩14.31 Billion | ₩149.12 Million | ₩13.18 Billion | ▲ +3205.3% |
| 2023 | 2.90x | ₩14.06 Billion | ₩4.84 Billion | ₩10.88 Billion | ▲ +4.7% |
| 2022 | 2.77x | ₩28.06 Billion | ₩10.13 Billion | ₩13.18 Billion | ▲ +143.5% |
| 2021 | 1.14x | ₩20.45 Billion | ₩17.97 Billion | ₩18.32 Billion | ▲ +20.5% |
| 2020 | 0.94x | ₩19.63 Billion | ₩20.80 Billion | ₩12.44 Billion | ▼ -18.6% |
| 2019 | 1.16x | ₩27.45 Billion | ₩23.67 Billion | ₩23.25 Billion | ▲ +256.4% |
| 2017 | 0.33x | ₩8.40 Billion | ₩25.81 Billion | ₩7.40 Billion | ▼ -79.3% |
| 2016 | 1.57x | ₩39.84 Billion | ₩25.33 Billion | ₩19.68 Billion | ▼ -76.0% |
| 2015 | 6.56x | ₩27.80 Billion | ₩4.24 Billion | ₩27.26 Billion | ▲ +423.9% |
| 2014 | 1.25x | ₩20.08 Billion | ₩16.04 Billion | ₩19.28 Billion | — |